TX-SPINALCYTE,-LLC
15.5.2019 16:20:11 CEST | Business Wire | Press release
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.
The company’s website, www.spinalcyte.com , now features company and independent research studies demonstrating the potential of this new cell source for disc repair and other disease pathways.
“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the Journal of Translational Medicine . “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”
SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.
“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005305/en/
Contact:
David Schull or Ned Berkowitz Russo Partners LLC 858-717-2310 646-942-5629 david.schull@russopartnersllc.com ned.berkowitz@russopartnersllc.com
Clinical Contact: info@spinalcyte.com
Link:
Social Media:
https://www.facebook.com/LibertyStarLBSR/#!/pages/Liberty-Star-Uranium-Metals-Corp/135810219778400?r
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
92% of Compliance Leaders Want External Certification on AI Agents. None Exists for On-Chain Risk. Elliptic Just Built It, for Free.20.10.2026 16:00:00 CEST | Press release
Elliptic Institute launches the first certification in agentic AI for on-chain risk and compliance, grounded in the principles of the Elliptic Standard. Elliptic, the leader in on-chain risk management, today launched the first certification in governing AI agents for on-chain risk and financial crime compliance from the Elliptic Institute. The Certified Agentic On-Chain Risk Practitioner (CAORP) Foundation Level is free and open to anyone in the industry. The certification follows new Elliptic research in which 92% of senior risk, compliance and financial crime professionals said they would consider sending staff for external certification in agentic AI risk governance. The global research1 found a wide gap between that appetite and teams' current capability. Only 16% of respondents said they were very confident their team has the skills to govern an AI agent today, while 38% said they were not confident at all or had no capability yet. Nearly a third (31%) expect to send staff for ce
Xceedance Named a Leader and Star Performer in Everest Group’s Insurance Intermediaries Operations PEAK Matrix® Assessment 202620.10.2026 16:00:00 CEST | Press release
Assessment highlights Xceedance’s MGA capabilities, strategic acquisitions, and intermediary-focused technology ecosystem Xceedance today announced it has been named a Leader and Star Performer in the Everest Group Insurance Intermediaries Operations PEAK Matrix® Assessment 2026. The assessment evaluated 18 providers based on market impact and their vision and capability to deliver insurance intermediary operations services. Everest Group identified Xceedance’s support for MGAs and MGUs across entity setup and licensing, underwriting, policy administration, finance, analytics, and claims as a key strength. The report also highlighted enabling rapid program launches and scaling through a licensed MGA shell, configurable workflows, and integrated operations. “Xceedance brings deep insurance expertise and a growing breadth of capabilities to support MGAs, brokers, and Lloyd’s market participants,” said Dinesh Udawat, Practice Director, Everest Group. “Its strategic acquisitions have expan
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 15:30:00 CEST | Press release
Practitioner-led agenda shows Europe’s CHROs, talent leaders and HRIT teams how to redesign work with AI, agents and automation Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMP
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge20.10.2026 15:26:00 CEST | Press release
Documentary follows ThinkMD, VectorCam, and Huna, the three award recipients from the inaugural Future Health Impact Challenge, delivered in collaboration with MIT Solve Prospective participants can now register to receive information about the second Future Health Impact Challenge ahead of its upcoming full launch Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugural Impact Challenge demonstrates the transformative power of innovative solutions that accelerate the shift from reactive to anticipatory healthcare systems. With scenes filmed in Kigali, Medellín, São Paulo, Boston, and Abu Dhabi, th
WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad20.10.2026 15:19:00 CEST | Press release
Dubai Electricity and Water Authority (DEWA) is organising the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 20 to 22 October 2026 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020867659/en/ WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad (Graphic: AETOSWire) “WETEX reflects the forward-looking vision of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to leverage innovation and advanced global technologies, including digital transformation, artificial intelligence (AI) and smart infrastructure, to strengthen the sustainability and resilience of the water and energy sectors while encouraging climate action,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA and Founder and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom